“I had the privilege of collaborating with Laure within my role at Kyowa Kirin International. It was a professionally rewarding experience that I greatly appreciated. Laure has the rare ability to see the big picture, develop a comprehensive strategy while understanding it's operational execution and ensuring deliverables are achieved. She is transparent, solution-oriented and exemplifies integrity and teamwork, effortlessly bringing together diverse stakeholders around a common vision and goal. She communicates clearly and effectively, inspiring and gaining support. She consistently demonstrates strong leadership by driving company performance, fostering development and ensuring employees and colleagues are valued and engaged.”
About
• 20 years of experience in strategy and commercialisation in pharma and life science…
Activity
-
Très heureux de participer au débat et à l’émission de Pharmaradio & Académie nationale de Pharmacie #mercredi8octobre2025 en #live de 12h à 14h30…
Très heureux de participer au débat et à l’émission de Pharmaradio & Académie nationale de Pharmacie #mercredi8octobre2025 en #live de 12h à 14h30…
Liked by Laure Nas de Tourris
-
Come and say hello to me at ISPOR! We have 15 HEOR and market access specialists at your disposal and would love to talk about your upcoming…
Come and say hello to me at ISPOR! We have 15 HEOR and market access specialists at your disposal and would love to talk about your upcoming…
Liked by Laure Nas de Tourris
Experience
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Education
-
Arts et Métiers ParisTech - École Nationale Supérieure d'Arts et Métiers
4th out of 1,100 students
-
Member of the Partners AM - alumni mentoring programme
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Volunteer Experience
-
Board Member - Deputy chair
The Ehlers-Danlos Support UK
- Present 3 years 6 months
Health
I joined the board of EDS UK as a trustee and director in June 2022. EDS UK was set up in 1987 to support, advise and inform those living with the Ehlers-Danlos syndromes. We aim to help them live a full, active and positive life. Over 30 years later, we remain the only UK based charity that exclusively represents and supports people with all types of EDS.
-
Honors & Awards
-
2019 Silver Spot Award: Global 10-year Strategic plan development with ExCom & shared with Board
UCB Pharma
-
2018 Silver Spot Award: Launch of Cimzia in Women of ChildBearing Age
UCB Pharma
-
2018 Silver spot award: Communication of strategy to the organization through leadership forum and company 3-year priorities
UCB Pharma
“From Task to Value”
-
2016 & 2017 Gold Spot Award: Leading Immunology 10-year plan
UCB Pharma
"From Noise to Signal"
-
2013 annual award: Primary Care field force strategy & reorganisation
Novartis Pharmaceuticals, Sydney
“Take ownership”
Languages
-
French
Native or bilingual proficiency
-
English
Full professional proficiency
-
Spanish
Limited working proficiency
Recommendations received
9 people have recommended Laure
Join now to viewOther similar profiles
Explore more posts
-
LifeArc
If you want to help create a future where: 1️⃣ people with rare diseases have faster diagnoses and better treatment options, and 2️⃣ innovators find a coordinated, sector-wide approach to get new tests and treatments to market, and help them stay there ➡️ read our latest report with Genetic Alliance UK: https://lnkd.in/e8iPr7Xi It recommends 10 actions that government, regulators, industry, academia, funders, clinicians, and patient groups can take to #ChangeTheRareFuture for those living with rare conditions.
-
Grant Thornton UK
🧬 The pharma services sector is experiencing rapid growth, driven by factors such as chronic diseases, regulation and R&D. 🔗 Our 'Ones to Watch' report highlights the most successful companies contributing to life sciences and the UK economy: https://okt.to/o0dMgx #PharmaServices #LifeSciences #MandA
1 Comment -
UCL Business Ltd
The UK’s life sciences sector is at a pivotal moment... Despite Merck’s and AstraZeneca’s recent announcements, there are reasons for optimism. The convergence of AI and health innovation is creating new opportunities for growth - especially in the spaces where universities, hospitals and investors collaborate. Our CEO, Anne Lane, has written an op-ed in the Financial Times about her optimism for the sector. She highlights that, at UCLB, we’ve seen firsthand how research breakthroughs can become commercial success stories: £3bn external in investment since 2020, and 100+ spinout companies creating 2300+ jobs. But the potential goes far beyond this. To truly unlock economic growth, the UK needs more early-stage funding to help academic research become market-ready, more scale-up venture capital and an easier-to-access NHS, to provide the market ‘pull’ for homegrown health innovations coming out of our universities. Read Anne's thoughts on what needs to change - and why the UK can still lead the next wave of medical breakthroughs (£): https://lnkd.in/eZGYiSc7
1 Comment -
Health Research Authority
We are delighted to join the World Health Organization's (WHO) new Global Clinical Trials Forum which officially launched earlier today. The forum is designed to strengthen clinical trial environments and infrastructure across the world. It will support the implementation of the WHO's Guidance for Best Practices for Clinical Trials, which saw the UK recognised as a country with a strong clinical trial infrastructure. Read more about the news by following the link in the comments below. #ClinicalTrials #Research #NHS #WHO #GlobalClinicalTrialsForum
1 Comment -
Hlx Life Sciences
📢 The UK just committed £2 billion to supercharge life sciences. It’s ambitious, bold and exactly what the sector needs. The Life Sciences Sector Plan sets out a roadmap to make the UK the #1 life sciences economy in Europe by 2030. But behind every investment, every trial, every tech breakthrough, there’s a team. And right now? That talent is the missing piece. The companies building the future of AI-powered diagnostics, genomics-enabled prevention, and decentralised clinical trials all have one thing in common: they need the right people, fast. That’s where Hlx comes in. If you're growing in life sciences or medtech, our talent strategies are built to match the pace of innovation. 👀 Swipe through to see what the plan covers — and how we can help you deliver it. #LifeSciences #MedTech #Biotech #UKLifeSciences #HealthTech #ClinicalTrials #Genomics #DigitalHealth #Innovation #HLX #NHSInnovation #R&D #TechBio #HealthcareTransformation #HiringForImpact
1 Comment -
Health Service Journal
One of the major topics facing the discussion panel at the HSJ Medicines Forum in London on the 16th October will be how NHS leaders are navigating a period of unprecedented change. With escalating financial pressures, widespread workforce reductions, and the disruptive effects of the recent NHS England reorganisation, maintaining high-quality patient care has become a significant challenge. Points for panel discussion will also include: -Financial Pressures: How are 50% ICB cost cuts affecting service delivery? -Structural Instability: What are the consequences of organisational mergers and the loss of institutional knowledge on system performance? -Workforce Morale: How are these changes impacting the morale of staff across pharmacy, commissioning, and frontline services? We're delighted to welcome Yousaf Ahmad to the panel at the forum. Yousaf will also be joined by Kandarp Thakkar and Paula Wilkinson FRPharmS to give us their unique insight into these key issues. There are just a handful of places now remaining for the HSJ Medicines Forum. To secure your place, or to find out more click here: https://lnkd.in/eSWrE4Yd #Medicines #HSJMedicines #Communitypharmacy #Pharmacy #NHS
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore More